To determine whether treatment with GP‐2250 affects upstream metabolites of glycolysis, we examined HK1 and HK2 mRNA and protein expression and activity levels in ovarian cancer cell lines (Figure 5A–C). This evidence concerns the gene HK1 and ovarian carcinoma.